Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04486781 · ClinicalTrials.gov registry record · Phase 2
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
A Phase 2 study of Metastatic Urothelial Carcinoma, sponsored by Vasgene Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT04486781 is a Phase 2 study of Metastatic Urothelial Carcinoma that is actively recruiting participants, run by Vasgene Therapeutics. The registered enrollment target is 38 participants, below the 129-participant average among 30 other Metastatic Urothelial Carcinoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04486781, a Phase 2 study of Metastatic Urothelial Carcinoma, is actively recruiting participants, sponsored by Vasgene Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to evaluate the combination of Pembrolizumab + sEphB4-HSA in the population of patients with previously untreated advanced (metastatic or recurrent) urothelial carcinoma who are chemotherapy ineligible or who refuse chemotherapy.
Conditions Studied
Interventions
- DRUG Pembrolizumab + sEphB4-HSA
Study Locations (1)
California
- Sarcoma Oncology Center - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2020-08-14 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04486781
The ClinicalTrials.gov registry entry for NCT04486781 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 129-participant average among 30 other Metastatic Urothelial Carcinoma trials with a reported enrollment target (71% lower). The listed sponsor is Vasgene Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab + sEphB4-HSA is the first listed.
NCT04486781 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04486781 about?
NCT04486781 is a clinical study titled "A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma". sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to evaluate the combination of Pembrolizumab + sEphB4-HSA in the population of patients with previously untreated a...
What is the current status of trial NCT04486781?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2020-08-14. Estimated completion is 2025-12-31.
What conditions does trial NCT04486781 study?
This clinical trial studies the following conditions: Metastatic Urothelial Carcinoma.
What interventions are being tested in trial NCT04486781?
The interventions under investigation include: Pembrolizumab + sEphB4-HSA (DRUG).
Who is sponsoring clinical trial NCT04486781?
This trial is sponsored by Vasgene Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04486781 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
RECRUITING · Phase 2
-
ARID1A and/or KDM6A Mutation and CXCL13 Expression
ACTIVE NOT RECRUITING · Phase 2
-
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.